

George Fountzilas

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1458905/george-fountzilas-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

244
papers

9,418
citations

42
h-index

90
g-index

251
ext. papers

10,795
ext. citations

5.3
avg, IF

4.91
L-index

#	Paper	IF	Citations
244	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology, The</i> , 2010 , 11, 753-62	21.7	1653
243	Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. <i>Lancet Oncology, The</i> , 2015 , 16, 645-55	21.7	453
242	Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 304-11 ²	11.2	435
241	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2	36.3	422
240	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1688-1700	21.7	328
239	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010 , 42, 885-92	36.3	276
238	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. <i>Nature Genetics</i> , 2011 , 43, 1210-4	36.3	253
237	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017 , 49, 680-691	36.3	190
236	What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 498-505	2.2	176
235	Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4068-75	2.2	167
234	Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3101-7	2.2	156
233	Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016 , 22, 704-13	12.9	138
232	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019 , 393, 1440-1452	40	137
231	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. <i>Carcinogenesis</i> , 2014 , 35, 1012-9	4.6	121
230	Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2870-8	2.2	115
229	Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. <i>Journal of Clinical Oncology</i> , 2015 , 33, 723-31	2.2	100
228	Common breast cancer susceptibility loci are associated with triple-negative breast cancer. <i>Cancer Research</i> , 2011 , 71, 6240-9	10.1	100

227	19p13.1 is a triple-negative-specific breast cancer susceptibility locus. <i>Cancer Research</i> , 2012 , 72, 1795-803.	3.1	93
226	Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. <i>Clinical Breast Cancer</i> , 2003 , 4, 120-5	3	93
225	Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 939-44	2.2	90
224	Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. <i>BMC Cancer</i> , 2013 , 13, 49	4.8	84
223	Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 6454-61	12.9	83
222	Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. <i>Medical Oncology</i> , 2004 , 21, 95-107	3.7	78
221	Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. <i>BMC Cancer</i> , 2008 , 8, 234	4.8	74
220	Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 353-62	4.4	73
219	Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. <i>PLoS ONE</i> , 2009 , 4, e7746	3.7	68
218	The upgraded role of HER3 and HER4 receptors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 74, 73-8	7	62
217	Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2018 , 36, 981-990	2.2	61
216	Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. <i>BMC Cancer</i> , 2013 , 13, 263	4.8	59
215	Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. <i>Cancer Investigation</i> , 2008 , 26, 784-93	2.1	58
214	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016 , 18, 15	8.3	58
213	XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. <i>BMC Cancer</i> , 2012 , 12, 271	4.8	54
212	Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. <i>Cancer Investigation</i> , 2000 , 18, 503-9	2.1	54
211	Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 131-43	4.4	53
210	Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. <i>Clinical Cancer Research</i> , 2010 , 16, 2427-34	12.9	52

209	A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 649-60	3.5	52
208	Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. <i>PLoS ONE</i> , 2012 , 7, e37946	3.7	49
207	Intraventricular administration of morphine for control of intractable cancer pain in 90 patients. <i>Neurosurgery</i> , 1996 , 39, 57-61; discussion 61-2	3.2	46
206	Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. <i>BMC Cancer</i> , 2005 , 5, 25	4.8	45
205	Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. <i>Oncotarget</i> , 2016 , 7, 5074-87	3.3	44
204	Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. <i>Clinical Breast Cancer</i> , 2012 , 12, 183-93	3	43
203	Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients. <i>European Journal of Cancer</i> , 2007 , 43, 443-53	7.5	43
202	Evaluation of six tumor markers in patients with carcinoma of unknown primary. <i>Medical and Pediatric Oncology</i> , 1994 , 22, 162-7		41
201	HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. <i>Journal of Translational Medicine</i> , 2012 , 10, 10	8.5	40
200	Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary. <i>Molecular Cancer</i> , 2013 , 12, 57	42.1	39
199	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 609-19	4.4	39
198	Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer. <i>BMC Cancer</i> , 2015 , 15, 334	4.8	38
197	Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 245-55	3.5	38
196	Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2006 , 96, 251-61	4.4	38
195	Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. <i>Breast Cancer Research</i> , 2018 , 20, 15	8.3	37
194	Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC). <i>PLoS ONE</i> , 2014 , 9, e94273	3.7	36
193	Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients. <i>Breast Cancer Research and Treatment</i> , 2008 , 107, 431-41	4.4	36
192	G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. <i>Breast Cancer Research and Treatment</i> , 2008 , 110, 377-85	4.4	35

191	Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). <i>Cancer Investigation</i> , 2004 , 22, 655-62	2.1	34
190	Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. <i>Radiotherapy and Oncology</i> , 2021 , 156, 281-293 ^{5,3}		34
189	Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. <i>Oncology</i> , 2009 , 76, 275-85	3.6	33
188	Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. <i>PLoS ONE</i> , 2013 , 8, e54048	3.7	33
187	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018 , 78, 5419-5430	10.1	32
186	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	31
185	Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer. <i>PLoS ONE</i> , 2013 , 8, e70429	3.7	31
184	Prognostic utility of Eubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 179-93	4.4	31
183	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017 , 82, 237-246	7.5	30
182	Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	30
181	The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. <i>Breast Cancer Research</i> , 2012 , 14, R145	8.3	30
180	EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 737-48	4.9	29
179	Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. <i>Breast Cancer Research and Treatment</i> , 2005 , 92, 1-9	4.4	29
178	Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. <i>Journal of Translational Medicine</i> , 2012 , 10, 212	8.5	28
177	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019 , 24, 521-528	5.7	28
176	Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer. <i>International Journal of Cancer</i> , 1999 , 80, 810-7	7.5	27
175	Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. <i>PLoS ONE</i> , 2015 , 10, e0140293	3.7	26
174	BRCA1 mutation analysis in breast/ovarian cancer families from Greece. <i>Human Mutation</i> , 2000 , 16, 272-3.7	3.7	26

173	MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. <i>Journal of Oncology</i> , 2009 , 2009, 305908	4.5	25
172	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. <i>Oncotarget</i> , 2016 , 7, 32731-53	3.3	25
171	Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer. <i>Strahlentherapie Und Onkologie</i> , 2014 , 190, 636-8, 640-5	4.3	24
170	Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) trials. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1418-1426	4.8	24
169	Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?. <i>Clinical and Experimental Metastasis</i> , 2007 , 24, 79-86	4.7	24
168	Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. <i>Anticancer Research</i> , 2011 , 31, 3007-18	2.3	24
167	Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. <i>Oncology</i> , 2009 , 77, 107-12	3.6	23
166	Radiation therapy and concurrent cisplatin administration in locally advanced head and neck cancer. A Hellenic Co-operative Oncology Group study. <i>Acta Oncologica</i> , 1994 , 33, 825-30	3.2	23
165	Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region. <i>Cancer</i> , 1990 , 66, 1453-60	6.4	23
164	Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2015 , 23, 2045-51	3.9	22
163	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020 , 80, 624-638	10.1	22
162	Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. <i>BMC Cancer</i> , 2014 , 14, 515	4.8	22
161	The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. <i>Breast</i> , 2014 , 23, 234-43	3.6	22
160	Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 533-46	3.5	21
159	A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. <i>Journal of Neurology</i> , 2013 , 260, 1469-80	5.5	21
158	Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer. <i>Pharmacogenomics</i> , 2015 , 16, 79-94	2.6	21
157	Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer. <i>Oral Oncology</i> , 2014 , 50, 298-305	4.4	21
156	Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. <i>PLoS ONE</i> , 2013 , 8, e58182	3.7	21

155	Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site. <i>Psycho-Oncology</i> , 2013 , 22, 2009-15	3.9	20
154	Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study. <i>Strahlentherapie Und Onkologie</i> , 2005 , 181, 223-30	4.3	20
153	Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. <i>Cancer Genomics and Proteomics</i> , 2017 , 14, 181-195	3.3	19
152	Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer. <i>ESMO Open</i> , 2019 , 4, e000474	6	19
151	Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. <i>Clinical Colorectal Cancer</i> , 2016 , 15, 164-9	3.8	18
150	Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial. <i>PLoS ONE</i> , 2015 , 10, e0124612	3.7	18
149	Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012 , 31, 77	12.8	18
148	Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors. <i>Clinical and Experimental Metastasis</i> , 2013 , 30, 431-9	4.7	18
147	Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. <i>Journal of Translational Medicine</i> , 2010 , 8, 108	8.5	18
146	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019 , 24, 491-497	5.7	17
145	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , 2015 , 64, 921-8	19.2	17
144	Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients. <i>BMC Clinical Pathology</i> , 2013 , 13, 1	3	17
143	Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. <i>Medical and Pediatric Oncology</i> , 1996 , 26, 305-17		17
142	MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. <i>Journal of Translational Medicine</i> , 2016 , 14, 136	8.5	17
141	Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 117-31	4.4	17
140	A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG). <i>BMC Cancer</i> , 2014 , 14, 111	4.8	16
139	Revising the radiobiological model of synchronous chemotherapy in head-and-neck cancer: a new analysis examining reduced weighting of accelerated repopulation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 157-63	4	16
138	Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS). <i>BMC Cancer</i> , 2012 , 12, 342	4.8	16

137	Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. <i>Oncology</i> , 2000 , 58, 227-36	3.6	16
136	In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients. <i>PLoS ONE</i> , 2014 , 9, e99131	3.7	16
135	Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial. <i>PLoS ONE</i> , 2018 , 13, e0200302	3.7	15
134	Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013 , 462, 141-54	5.1	15
133	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 117-134	4.4	15
132	Bevacizumab in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2010 , 36, 75-82	14.4	15
131	Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation. <i>Clinical and Experimental Metastasis</i> , 1998 , 16, 665-72	4.7	15
130	Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. <i>Oncology</i> , 2007 , 72, 388-96	3.6	15
129	Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes. A feasibility study. <i>Oncology</i> , 1998 , 55, 508-12	3.6	15
128	Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e370-e384	3.8	14
127	The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 267-274.e2	3.8	14
126	Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>European Journal of Epidemiology</i> , 2012 , 27, 857-66	12.1	14
125	G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. <i>Cancer</i> , 2001 , 91, 909-917	6.4	14
124	The Role of CXCL13 and CXCL9 in Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020 , 20, e36-e53	3	14
123	The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases. <i>Clinical Epigenetics</i> , 2017 , 9, 46	7.7	13
122	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. <i>Translational Oncology</i> , 2017 , 10, 589-598	4.9	13
121	FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 14-26.e1	3.8	13
120	Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary. <i>Clinical and Experimental Metastasis</i> , 2012 , 29, 603-14	4.7	13

119	Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study. <i>Journal of Neuro-Oncology</i> , 1999 , 45, 159-65	4.8	13
118	Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG). <i>PLoS ONE</i> , 2013 , 8, e70634	3.7	13
117	Evaluation of two highly-multiplexed custom panels for massively parallel semiconductor sequencing on paraffin DNA. <i>PLoS ONE</i> , 2015 , 10, e0128818	3.7	13
116	Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials. <i>Cancer Medicine</i> , 2016 , 5, 17-23	4.8	13
115	Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. <i>Anticancer Research</i> , 2006 , 26, 4675-86	2.3	13
114	Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. <i>Journal of Translational Medicine</i> , 2017 , 15, 30	8.5	12
113	One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene. <i>Journal of Medical Genetics</i> , 2020 , 57, 53-61	5.8	12
112	High-Dose Epirubicin as a Single Agent in the Treatment of Patients with Advanced Breast Cancer. <i>Tumori</i> , 1991 , 77, 232-236	1.7	12
111	Protein expression patterns of cell cycle regulators in operable breast cancer. <i>PLoS ONE</i> , 2017 , 12, e0180489	3.7	12
110	Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer. <i>Oncotarget</i> , 2018 , 9, 35623-35638	3.3	12
109	Tumor Infiltrating Lymphocytes and CD8+ T Cell Subsets as Prognostic Markers in Patients with Surgically Treated Laryngeal Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2020 , 14, 689-700	3.3	12
108	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 307-21	4.4	12
107	Gemcitabine Combined with the mTOR Inhibitor Temozolomide in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study. <i>Targeted Oncology</i> , 2018 , 13, 715-724	5	12
106	Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays. <i>Anticancer Research</i> , 2013 , 33, 2139-45	2.3	12
105	Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe. <i>International Journal of Cancer</i> , 2018 , 142, 66-80	7.5	11
104	The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer. <i>BMC Neurology</i> , 2016 , 16, 190	3.1	11
103	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014 , 23, 6034-46	5.6	11
102	Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG). <i>Journal of Neuro-Oncology</i> , 2017 , 134, 443-451	4.8	11

101	Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. <i>Journal of Translational Medicine</i> , 2015 , 13, 171	8.5	11
100	Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. <i>PLoS ONE</i> , 2013 , 8, e69256	3.7	11
99	Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>Oncology Reports</i> , 2012 , 27, 216-24	3.5	11
98	Long-term survival data and prognostic factors of a complete response to chemotherapy in patients with head and neck cancer treated with platinum-based induction chemotherapy: a Hellenic Co-operative oncology Group study. <i>Medical and Pediatric Oncology</i> , 1997 , 28, 401-10		11
97	Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes. <i>PLoS ONE</i> , 2014 , 9, e91407	3.7	11
96	alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies. <i>BMC Clinical Pathology</i> , 2014 , 14, 28	3	10
95	Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer. <i>PLoS ONE</i> , 2018 , 13, e0208221	3.7	10
94	Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVER Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. <i>Cancers</i> , 2021 , 13,	6.6	10
93	Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2016 , 16, 291-298.e3	3	9
92	Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2014 , 14, 330-8	3	9
91	Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group. <i>ESMO Open</i> , 2020 ,	6	9
90	Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 1549-1564	7.4	9
89	p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab. <i>Pathology and Oncology Research</i> , 2015 , 21, 273-82	2.6	8
88	AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI+ Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e631-e637	3.8	8
87	DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome. <i>Pathology and Oncology Research</i> , 2013 , 19, 329-43	2.6	8
86	STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN. <i>Translational Oncology</i> , 2011 , 4, 47-58	4.9	8
85	A Randomized Open-Label Parallel-Group Study Comparing Ondansetron with Ondansetron plus Dexamethasone in Patients with Metastatic Breast Cancer Receiving High-Dose Epirubicin. A Hellenic Cooperative Oncology Group Study. <i>Tumori</i> , 2000 , 86, 37-41	1.7	8
84	Treatment of unresectable recurrent head and neck carcinoma with 13-cis-retinoic acid and interferon-alpha. A phase II study. <i>Journal of Laryngology and Otology</i> , 1996 , 110, 857-61	1.8	8

83	Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. <i>PLoS ONE</i> , 2016 , 11, e0163138	3.7	8
82	Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal Cancer. <i>Anticancer Research</i> , 2019 , 39, 2129-2138	2.3	7
81	Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2019 , 16, 195-206	3.3	7
80	CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases. <i>Cancer Genetics</i> , 2015 , 208, 129-34	2.3	7
79	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 217-228	4	7
78	Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer. <i>Medical Oncology</i> , 2006 , 23, 479-88	3.7	7
77	Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Study. <i>Medical Oncology</i> , 2005 , 22, 269-79	3.7	7
76	High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group study. <i>Medical and Pediatric Oncology</i> , 1995 , 24, 23-8		7
75	Carboplatin, Continuous Infusion Fluorouracil and Mid-cycle High-dose Methotrexate as Initial Treatment in Patients with Locally Advanced Head and Neck Cancer. <i>Tumori</i> , 1991 , 77, 426-431	1.7	7
74	Cancer Risks Associated With and Pathogenic Variants.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102112	2.2	7
73	Is There an Independent Role of TERT and NF1 in High Grade Gliomas?. <i>Translational Oncology</i> , 2020 , 13, 346-354	4.9	7
72	PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 1289-301	3.5	6
71	Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. <i>Cancer Investigation</i> , 2008 , 26, 491-8	2.1	6
70	Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. <i>Clinical and Experimental Metastasis</i> , 2000 , 18, 313-9	4.7	6
69	Megestrol acetate in cancer patients with anorexia and weight loss. A Hellenic Co-operative Oncology Group (HeCOG) study. <i>Acta Oncologica</i> , 1993 , 32, 37-41	3.2	6
68	Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2017 , 37, 2323-2334	2.3	6
67	Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients. <i>Gynecologic Oncology</i> , 2019 , 152, 375-386	4.9	6
66	Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. <i>Cancer Medicine</i> , 2018 , 7, 5066-5082	4.8	6

65	Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas. <i>Cancer Genomics and Proteomics</i> , 2018 , 15, 421-436	3.3	6
64	Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab. <i>Cancer Genomics and Proteomics</i> , 2018 , 15, 461-471	3.3	6
63	Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. <i>Medical Oncology</i> , 2018 , 35, 101	3.7	6
62	Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial. <i>Anticancer Research</i> , 2017 , 37, 2947-2957	2.3	6
61	Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial. <i>British Journal of Cancer</i> , 2020 , 123, 355-361	8.7	5
60	Cisplatin and continuous infusion of fluorouracil followed by radiation and weekly carboplatin in the treatment of locally advanced head and neck cancer: a Hellenic Cooperative Oncology Group study. <i>Cancer Investigation</i> , 1996 , 14, 189-96	2.1	5
59	Carboplatin and Oral Etoposide in the Treatment of Patients with Advanced Breast Cancer Refractory to Anthracyclines. <i>Tumori</i> , 1993 , 79, 389-392	1.7	5
58	Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers. <i>American Journal of Cancer Research</i> , 2018 , 8, 2-15	4.4	5
57	The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy. <i>Anticancer Research</i> , 2017 , 37, 2947-2957	2.3	5
56	Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	5
55	Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG). <i>ESMO Open</i> , 2019 , 4, e000525	6	5
54	Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome. <i>Clinical Breast Cancer</i> , 2019 , 19, 113-125.e4	3	5
53	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. <i>Clinical Breast Cancer</i> , 2018 , 18, 53-62.e3	3	5
52	Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients. <i>Journal of Human Genetics</i> , 2018 , 63, 877-886	4.3	5
51	Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2016 , 36, 2365-78	2.3	5
50	PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk. <i>Journal of Human Genetics</i> , 2019 , 64, 767-773	4.3	4
49	Crizotinib Failure in a -Rearranged Inflammatory Myofibroblastic Tumor With an Emerging Kinase Domain Mutation.. <i>JCO Precision Oncology</i> , 2017 , 1, 1-7	3.6	4
48	Prognostic significance of WNT and hedgehog pathway activation markers in cancer of unknown primary. <i>European Journal of Clinical Investigation</i> , 2015 , 45, 1145-52	4.6	4

47	Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer. <i>Cancer Investigation</i> , 2001 , 19, 137-44	2.1	4
46	Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. <i>PLoS ONE</i> , 2016 , 11, e0164013	3.7	4
45	Disease evolution and heterogeneity in bilateral breast cancer. <i>American Journal of Cancer Research</i> , 2016 , 6, 2611-2630	4.4	4
44	The fate of BRCA1-related germline mutations in triple-negative breast tumors. <i>American Journal of Cancer Research</i> , 2017 , 7, 98-114	4.4	4
43	SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Journal of Translational Medicine</i> , 2019 , 17, 429	8.5	4
42	Prevalence and founder effect of the BRCA1 p.(Val1833Met) variant in the Greek population, with further evidence for pathogenicity and risk modification. <i>Cancer Genetics</i> , 2019 , 237, 90-96	2.3	3
41	Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC). <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015 , 23, 60-70	1.9	3
40	First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study. <i>Anticancer Research</i> , 2020 , 40, 929-938	2.3	3
39	Genotyping and Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment. <i>Cancer Genomics and Proteomics</i> , 2019 , 16, 531-541	3.3	3
38	Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17. <i>PLoS ONE</i> , 2014 , 9, e103707	3.7	3
37	A retrospective cohort study of PD-L1 expression in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SUPREME-HN).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6040-6040	2.2	3
36	A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. <i>PLoS ONE</i> , 2014 , 9, e86375	3.7	3
35	Comparison of somatic variant detection algorithms using Ion Torrent targeted deep sequencing data. <i>BMC Medical Genomics</i> , 2019 , 12, 181	3.7	3
34	Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab. <i>ESMO Open</i> , 2019 , 4, e000441	6	2
33	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2020 , 17, 181-193	3.3	2
32	Accelerated Bifractionated Radiation with Concurrent Cisplatin Administration in Locally Advanced Head and Neck Cancer: A Feasibility Study. <i>Tumori</i> , 1997 , 83, 735-739	1.7	2
31	Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients.. <i>Clinical and Translational Radiation Oncology</i> , 2022 , 32, 59-68	4.6	2
30	Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer. <i>Cancer Genomics and Proteomics</i> , 2020 , 17, 529-541	3.3	2

29	AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study. <i>Acta Oncologica</i> , 2021 , 60, 785-793	3.2	2
28	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. <i>Human Genetics and Genomics Advances</i> , 2021 , 2, 100042-100042	0.8	2
27	The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. <i>International Journal of Clinical Oncology</i> , 2019 , 24, 411-419	4.2	2
26	Impact of Bevacizumab Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group. <i>Anticancer Research</i> , 2020 , 40, 2095-2106	2.3	2
25	Genotype-phenotype associations in colorectal adenocarcinomas and their matched metastases. <i>Human Pathology</i> , 2021 , 107, 104-116	3.7	2
24	Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study. <i>Histology and Histopathology</i> , 2015 , 30, 1129-41	1.4	2
23	Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab. <i>Translational Oncology</i> , 2019 , 12, 739-748	4.9	1
22	Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study. <i>Biology</i> , 2020 , 9,	4.9	1
21	Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy. <i>Cancer Genomics and Proteomics</i> , 2020 , 17, 277-290	3.3	1
20	Adjuvant cytotoxic and endocrine therapy in pre- and postmenopausal patients with breast cancer and one to nine infiltrated nodes: five-year results of the Hellenic Cooperative Oncology Group randomized HE 10/92 study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 57-67	2.7	1
19	Overview of advances in cancer immunotherapy. <i>Annals of Translational Medicine</i> , 2016 , 4, 260	3.2	1
18	Genetic Variations of Gene Are Associated With Infiltration of Adjacent Tissues and the Clinical Outcome of Patients With Nasopharyngeal Carcinoma. <i>Anticancer Research</i> , 2020 , 40, 677-688	2.3	1
17	Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer. <i>Anticancer Research</i> , 2016 , 36, 6347-6356	2.3	1
16	Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer. <i>Anticancer Research</i> , 2021 , 41, 1793-1802	2.3	1
15	Genotyping data of routinely processed matched primary/metastatic tumor samples. <i>Data in Brief</i> , 2021 , 34, 106646	1.2	1
14	Androgen Receptor and Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2021 , 18, 147-156	3.3	1
13	Treating EGFR-Mutated Oncogene-Addicted Advanced Non-Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities. <i>Journal of Global Oncology</i> , 2018 , 4, 1-12	2.6	1
12	Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study. <i>PLoS ONE</i> , 2018 , 13, e0207707	3.7	1

11	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 6156-6163	12.9	1
10	When cascade testing for familial variant seems inadequate to provide clinically actionable information for blood relatives. <i>Cancer Genetics</i> , 2021 , 258-259, 49-50	2.3	1
9	Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. <i>Cancers</i> , 2021 , 13,	6.6	1
8	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. <i>Oncotarget</i> , 2020 , 11, 1-14	3.3	0
7	An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. <i>Lung Cancer: Targets and Therapy</i> , 2021 , 12, 93-102	2.9	0
6	Lung cancer as a predominant feature in a patient with Peutz-Jeghers syndrome: Case report.. <i>Thoracic Cancer</i> , 2022 ,	3.2	0
5	DCC and TS protein expression in resected gastric cancer: A Hellenic Cooperative Oncology Group Study. <i>Open Medicine (Poland)</i> , 2008 , 3, 29-39	2.2	
4	mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab. <i>Oncology Letters</i> , 2022 , 23, 23	2.6	
3	Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?. <i>Frontiers in Oncology</i> , 2021 , 11, 683057	5.3	
2	Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries. <i>Breast Cancer</i> , 2021 , 28, 1367-1382	3.4	
1	HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study. <i>Anticancer Research</i> , 2016 , 36, 1581-90	2.3	